Click on the newsitems to get more information.
Batavia Bioservices BV and UvA Holding BV announced today that they have successfully concluded an agreement granting Batavia Bioservices the exclusive rights to STEP(TM) technology developed by scientists at CellaGenics BV, an UvA Holding BV company.
Under the agreement, Batavia Bioservices has been granted the exclusive license to the STEP(TM) technology, a revolutionary, plasmid-based system that significantly reduces the time required to develop recombinant protein-producing mammalian cell lines while increasing protein production more then 10-fold.
Menzo Havenga (CEO Batavia Bioservices) commented: "We are very pleased that UvA Holding has selected Batavia Bioservices as its marketing partner for STEP(TM) technology since we firmly believe that this technology will significantly reduce manufacturing costs. Chris Yallop (COO Batavia Bioservices) added: "STEP(TM) technology also allows the development of so-called rare diseases biopharmaceutical products, which have always been considered too expensive to develop. Piet Scholten (Director UvA Holding BV) concluded: "With their in-depth know how in biopharm manufacturing, vast network, and presence in both Europe and USA, Batavia Bioservices provided the ideal landing platform for marketing our technology and we look forward to a fruitful relationship!"
Batavia Bioservices is pleased to announce a new partnership, allowing us to offer to our clients a seamless transition from cell line development through to cell banking, characterization, and clinical scale manufacturing of recombinant proteins, mAbs, gene therapies and virus products on a global level.
With GMP manufacturing facilities located in Leiden, Netherlands and also facilities in Massachusetts, Batavia Bioservices provides clinical scale manufacturing of proteins, antibodies, vaccines and vectors, and assists clients with cell line development, mammalian and microbial cell culture process development and purification process development.
This partnership with Charles River Biopharmaceutical Services (BPS) will help advance our goal of making the development of drug products and vaccines as easy as possible for clients. Aided by the experience, scientific expertise, and testing facilities and capabilities of Charles River, Batavia Bioservices is able to provide clients with an even more complete solution for their early-stage drug product and vaccine development and manufacturing needs.
Batavia Bioservices herewith announces that it will participate in a SME partnership program from TI Pharma. Within the project called "CXE1 as treatment for CVD" Batavia Bioservices will be involved in the pre-clinical and early clinical development of an exciting, novel candidate medicine for treatment of myocardial infarction. The consortium that was awarded this TI Pharma SME partnership call 2012 consists of the University of Utrecht, CardioGenX BV and Batavia Bioservices BV. Menzo Havenga (CEO Batavia Bioservices) commented: “we are very pleased that we have been awarded this program by TI Pharma and we look very much forward to working with our partners on this exciting project”. The program is scheduled to start January 2013.
Batavia Bioservices herewith announces that it will participate in a SME partnership program titled "Off-the-shelf-antigen-loaded dendritic cell vaccines" Batavia Bioservices will be involved in the development of assays to determine potency and stability of novel cancer vaccines. The consortium that was awarded this TI Pharma SME partnership call 2012 consists of the Leiden University Medical Center, DCPrime BV and Batavia Bioservices BV. Chris Yallop (COO Batavia Bioservices) commented: "This is an exciting program for our scientists working in our Analytical Assay Department and we look forward working on this novel vaccine platform with our partners". The program is scheduled to start January 2013.
Batavia Bioservices launches laboratory infrastructure in Greater Boston area. As of February 2012 Batavia Bioservices deploys 5.300 square feet of laboratories at 300 TradeCenter, Suite 6650, Woburn, MA 01801. The dedicated BSL-2 laboratories have been fully equipped to offer to our customers high quality DNA preparative services, transient protein production, stable pharmaceutical grade cell line generation (mammalian), viral vector generation, and microbial fermentation. The company is pleased that it has been able to attract industrial professionals that are recognized experts in mammalian or microbial upstream and downstream processing as well as virologists and molecular biologists. It is expected that the Woburn site will be fully operational and will start to execute customer contracts as of May first 2012.
Batavia Bioservices is proud to announce that it has been awarded a prestigious European grant (FP7-program) UNDER THE MARIE CURIE INITIAL TRAINING NETWORK (ITN). The program, which is executed by a consortium of world class industrial and academic partners and COORDINATED by Professor A. Baker (University of Glasgow, UK) focuses on the development of novel adenoviral vectors for gene therapy and vaccine development. Professor Andrew Baker explained: True innovations in healthcare are pivotal to be able to effectively treat diseases like cardiovascular disease AND CANCER in the future. I am therefore very pleased that we have been awarded this grant by the European Union in the hope that we can develop breakthrough technology. The role of Batavia Bioservices in the program is to significantly improve vector manufacturing parameters with the intent to make the technology more cost effective.
for more information click here >>
Batavia Bioservices is proud to announce that the company will participate in a prestigious grant from the Bill and Melinda Gates Foundation awarded to Beth Israel Deaconess Medical Center (BIDMC), a major teaching hospital of Harvard Medical School. This grant will fund the development and clinical evaluation of a novel candidate AIDS vaccine based on recombinant vector technology. Dr. Dan Barouch, Chief of the Division of Vaccine Research at BIDMC commented: “This grant provides us with the opportunity to evaluate a novel and promising vaccine strategy for HIV-1”. Batavia Bioservices is a key subcontractor for this project and will conduct the process development and clinical manufacturing of this candidate vaccine.
Today Batavia Bioservices BV and Xendo BV announce that they have initiated a strategic business collaboration. As a consequence, all Bioprocess activities of Xendo Manufacturing BV have been transferred to Batavia Bioservices BV. This provides Batavia Bioservices BV access to unique simulated moving bed (SMB) purification technology as well as infrastructure, knowledge and experience in microbial process and product development. At the same time, the companies will establish joint marketing efforts whereby Xendo BV will provide engineering, regulatory and clinical support services and Batavia Bioservices will provide process development and analytical services.
Menzo Havenga (CEO, Batavia Bioservices BV) explains: "Xendo BV and Batavia Bioservices BV together have more critical mass and therefore are able to execute larger, more complex customer programs. It is fully expected that our collaboration will result in more customers being offered a complete development services package. André van de Sande, CEO Xendo BV, adds: I trust that by combining our forces both companies are better positioned to service our customers. This helps Xendo BV, both in the Netherlands and international, to further expand."
Information on Xendo BV
Xendo is a leading, independent consultancy and project management organization in the life sciences, pharmaceutical and healthcare fields. Our ambition is to enhance the quality and safety of medicine and help shorten the time to market for drugs and medical devices that improve the quality of life.
Xendo was established in 1990 (originally under the name of Univalid) and is fully privately owned.
Xendo has offices in Leiden (headquarter) and in Berlin. The company employs close to a hundred employees and has its own in-house QA and Knowledge management center and is ISO 9001 certified.
More information on Xendo can be found on www.xendo.com.
Batavia Bioservices is pleased to announce that it has successfully engaged
Dr. David Hone and Dr. Tineke Meijers (North America) and Dr Michael Murray (United Kingdom) to strengthen the marketing and sales activities of the company.
Dr. David Hone is a biotech professional with more than 25 years of experience in executive positions in both for-profit and non-profit organizations. During his career he has build an extensive network in the biotechnology field in particular with small and midsize life sciences companies in the USA. David will focus on the development and strategic business relationships and marketing of Batavia Bioservices products and services, specifically to the US market.
Dr. Tineke Meijers has more than 15 years of experience in global marketing and business development in the pharmaceutical and Biotech industry. She has served as a consultant to numerous pharmaceutical and Biotech companies in both USA and Canada and she is currently actively involved in marketing activities for several for-profit and non-profit organizations. Tineke will focus on the development and strategic business relationships and marketing of Batavia Bioservices products and services specifically to the North American markets.
Dr. Michael Murray has been for more than 25 years serving the Biotechnology industry in leading executive positions in both for-profit and non-profit organizations. In his role as Senior Vice President Business development in diverse organizations he has build an extensive network in the field of life Sciences in the United Kingdom and across Europe. Mike will focus on the development and strategic business relationships and marketing of Batavia Bioservices products and services specifically to the UK market.
Because of their extensive experience and know how in the Biotechnology field, all three are actively serving as members on diverse scientific boards, advisory committees, grant review panels, and private investment committees.
CEO, Menzo Havenga commented: "It has been a great pleasure to work with David, Tineke and Mike in the past and undoubtedly they bring a wealth of knowledge and vast network to Batavia Bioservices. We are extremely happy that they have chosen to work with us and we look very much forward to continuing our fruitful relationship".
Batavia Bioservices B.V. is pleased to announce that it has launched a wholly owned US subsidiary, Batavia Bioservices Inc., with offices in the Rockville innovation Center, 155, Gibbs Street, Suite 521, Rockville, MD20850. The location for the office in Montgomery County was chosen since this region is home to more than 500 biotech companies, the National institutes of Health, the University of Maryland and many highly respected health care institutes such as WRAIR and NMRC. The incorporation of the US subsidiary and opening of offices represent an important step towards the desired expansion of Batavia’s customer base in the United States and represent a major first step in building a physical presence in the USA.
In order to meet growing customer demand, the company has decided to significantly expand its operations in the Gaubius Building of the Leiden Bioscience Park, The Netherlands. The additional offices and laboratories will support an expansion of our services in upstream process development, downstream process development, assay development, and molecular virology. It is expected that the new infrastructure will be fully operational as of February 2011.